National Bank of Canada FI Invests $713,000 in REGENXBIO Inc. (NASDAQ:RGNX)

National Bank of Canada FI bought a new stake in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 68,000 shares of the biotechnology company's stock, valued at approximately $713,000. National Bank of Canada FI owned about 0.14% of REGENXBIO at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. FMR LLC increased its holdings in shares of REGENXBIO by 166.8% in the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 1,656 shares during the last quarter. nVerses Capital LLC raised its holdings in shares of REGENXBIO by 183.3% during the third quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company's stock worth $36,000 after purchasing an additional 2,200 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in shares of REGENXBIO by 64.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company's stock worth $100,000 after buying an additional 3,720 shares during the last quarter. Diversified Trust Co acquired a new position in shares of REGENXBIO in the 2nd quarter valued at about $121,000. Finally, Arizona State Retirement System grew its position in shares of REGENXBIO by 20.6% during the 2nd quarter. Arizona State Retirement System now owns 11,669 shares of the biotechnology company's stock valued at $137,000 after buying an additional 1,997 shares during the last quarter. 88.08% of the stock is currently owned by hedge funds and other institutional investors.

REGENXBIO Stock Performance

Shares of NASDAQ:RGNX traded down $0.44 during mid-day trading on Friday, hitting $8.28. The stock had a trading volume of 1,466,752 shares, compared to its average volume of 1,206,801. The company's 50 day moving average is $9.74 and its 200-day moving average is $11.38. REGENXBIO Inc. has a 12-month low of $8.26 and a 12-month high of $28.80. The company has a market cap of $410.19 million, a PE ratio of -1.65 and a beta of 1.24.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on RGNX. Raymond James reissued an "outperform" rating and issued a $18.00 target price on shares of REGENXBIO in a report on Thursday, October 10th. StockNews.com upgraded REGENXBIO from a "sell" rating to a "hold" rating in a research report on Friday, September 20th. HC Wainwright cut their target price on REGENXBIO from $40.00 to $36.00 and set a "buy" rating on the stock in a research note on Thursday, November 21st. Chardan Capital reaffirmed a "buy" rating and issued a $52.00 price objective on shares of REGENXBIO in a report on Wednesday, November 20th. Finally, Morgan Stanley restated an "overweight" rating and issued a $22.00 target price on shares of REGENXBIO in a research report on Friday, November 15th. Two research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $35.27.

Insider Activity at REGENXBIO

In other news, Director Argeris N. Karabelas sold 10,000 shares of the firm's stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $10.11, for a total transaction of $101,100.00. Following the completion of the sale, the director now directly owns 11,286 shares of the company's stock, valued at $114,101.46. This trade represents a 46.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 13.13% of the stock is owned by insiders.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.